Publications by authors named "Ignacio Darnaude Ximenez"
Article Synopsis
- A study evaluated the pharmacokinetics of Isavuconazole (ISA) in 13 lung transplant recipients, focusing on how well the drug penetrates lung tissue.
- The results showed mean serum concentrations of ISA at 2, 4, and 24 hours post-administration: 3.30, 5.12, and 6.31, respectively.
- Additionally, the drug reached effective levels in the epithelial lining fluid of the lungs, indicating it is safe and effective for use in this patient population.
Bronchopulmonary Penetration of Isavuconazole in Pulmonary Transplant Recipients (PBISA01): Protocol for a Phase IV Clinical Trial With a Single Treatment Arm.
Ignacio Darnaude-Ximénez Antonio F Caballero-Bermejo Belén Ruiz-Antorán Myriam Aguilar-Pérez Alicia Gómez-López
JMIR Res Protoc
September 2022
Background: Aspergillosis is the most frequently observed invasive fungal disease (IFD) in lung transplant recipients. Isavuconazole (ISA) has shown a better safety profile and noninferiority to voriconazole in the treatment of patients with IFD.
Objective: The aim of this study is to describe the bronchopulmonary pharmacokinetic profile of oral ISA by analyzing the degree of penetration in the epithelial lining fluid and alveolar macrophages in patients receiving lung transplantation with a diagnosis of IFD.